INMED PHARMACEUTICALS INC. Operating Expenses
INMED PHARMACEUTICALS INC. (INM) reported Operating Expenses of $11.61 million for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. operating expenses for the quarter ending 2026-06-30 was $4.86M, a 160.48% increase year-over-year.
- INMED PHARMACEUTICALS INC. operating expenses for the quarter ending 2026-03-31 was $2.84M, a 36.28% increase year-over-year.
- INMED PHARMACEUTICALS INC. operating expenses for the quarter ending 2025-12-31 was $2.29M, a 15.77% decline year-over-year.
- INMED PHARMACEUTICALS INC. operating expenses for the quarter ending 2025-09-30 was $2.22M, a 0.20% decline year-over-year.
- INMED PHARMACEUTICALS INC. operating expenses for fiscal 2023 was $9.83M, a 44.80% decline from fiscal 2022.
- INMED PHARMACEUTICALS INC. operating expenses for fiscal 2022 was $17.81M, a 79.18% increase from fiscal 2021.
- INMED PHARMACEUTICALS INC. operating expenses for fiscal 2021 was $9.94M, a 8.60% increase from fiscal 2020.
- INMED PHARMACEUTICALS INC. operating expenses for fiscal 2020 was $9.15M.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.86M derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $7.70M derived: sum of 2 quarters · filed 2026-09-09 | $9.99M derived: sum of 3 quarters · filed 2026-09-09 | $11.61M S-4/A · filed 2026-09-09 | ||||
| 2026-03-31 | $2.84M S-4 · filed 2026-07-02 | $5.13M derived: sum of 2 quarters · filed 2026-07-02 | $6.75M S-4 · filed 2026-07-02 | $9.22M derived: sum of 4 quarters · filed 2026-09-09 | ||||
| 2025-12-31 | $2.29M 10-Q · filed 2026-02-11 | $4.51M 10-Q · filed 2026-02-11 | $6.38M derived: sum of 3 quarters · filed 2026-09-09 | $8.46M derived: sum of 4 quarters · filed 2026-09-09 | ||||
| 2025-09-30 | $2.22M 10-Q · filed 2025-11-06 | $4.09M derived: sum of 2 quarters · filed 2026-09-09 | $6.17M derived: sum of 3 quarters · filed 2026-09-09 | $8.89M derived: sum of 4 quarters · filed 2026-09-09 | ||||
| 2025-06-30 | $1.87M derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $3.95M derived: sum of 2 quarters · filed 2026-09-09 | $6.66M derived: sum of 3 quarters · filed 2026-09-09 | $8.47M S-4/A · filed 2026-09-09 | $9.65M 10-K · filed 2025-09-23 | |||
| 2025-03-31 | $2.08M S-4 · filed 2026-07-02 | $2.31M 10-Q · filed 2025-05-12 | $4.80M derived: sum of 2 quarters · filed 2026-07-02 | $6.61M S-4 · filed 2026-07-02 | $7.26M 10-Q · filed 2025-05-12 | $9.53M derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2024-12-31 | $2.71M 10-Q · filed 2026-02-11 | $4.94M 10-Q · filed 2026-02-11 | $7.44M derived: sum of 3 quarters · filed 2026-07-02 | $9.58M derived: sum of 4 quarters · filed 2026-07-02 | ||||
| 2024-09-30 | $2.23M 10-Q · filed 2025-11-06 | $4.73M derived: sum of 2 quarters · filed 2026-07-02 | $6.86M derived: sum of 3 quarters · filed 2026-07-02 | $8.83M derived: sum of 4 quarters · filed 2026-07-02 | ||||
| 2024-06-30 | $2.50M derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $4.63M derived: sum of 2 quarters · filed 2026-07-02 | $6.60M derived: sum of 3 quarters · filed 2026-07-02 | $9.30M S-4 · filed 2026-07-02 | ||||
| 2024-03-31 | $2.13M 10-Q · filed 2025-05-12 | $4.10M derived: sum of 2 quarters · filed 2025-05-12 | $6.80M 10-Q · filed 2025-05-12 | $8.93M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $1.97M 10-Q · filed 2025-02-12 | $4.66M 10-Q · filed 2025-02-12 | $6.80M derived: sum of 3 quarters · filed 2025-02-12 | $9.14M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-09-30 | $2.69M 10-Q · filed 2024-11-14 | $4.83M derived: sum of 2 quarters · filed 2024-11-14 | $7.17M derived: sum of 3 quarters · filed 2024-11-14 | $9.52M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $4.48M derived: sum of 2 quarters · filed 2024-09-30 | $6.82M derived: sum of 3 quarters · filed 2024-09-30 | $9.83M 10-K · filed 2024-09-30 | $9.78M 10-K · filed 2023-09-29 | |||
| 2023-03-31 | $2.34M 10-Q · filed 2023-05-15 | $4.69M derived: sum of 2 quarters · filed 2024-02-13 | $7.70M 10-Q · filed 2023-05-15 | $14.54M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-12-31 | $2.35M 10-Q · filed 2024-02-13 | $2.37M 10-Q · filed 2023-02-17 | $5.43M 10-Q · filed 2024-02-13 | $5.35M 10-Q · filed 2023-02-17 | $12.20M derived: sum of 3 quarters · filed 2024-02-13 | $15.92M derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-09-30 | $3.08M 10-Q · filed 2023-11-14 | $2.99M 10-Q · filed 2022-11-14 | $9.85M derived: sum of 2 quarters · filed 2023-11-14 | $13.58M derived: sum of 3 quarters · filed 2023-11-14 | $18.00M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $10.49M derived: sum of 2 quarters · filed 2023-09-29 | $14.92M derived: sum of 3 quarters · filed 2023-09-29 | $17.81M 10-K · filed 2023-09-29 | ||||
| 2022-03-31 | $3.72M 10-Q · filed 2023-05-15 | $8.15M derived: sum of 2 quarters · filed 2023-05-15 | $11.04M 10-Q · filed 2023-05-15 | $14.34M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $4.42M 10-Q · filed 2023-02-17 | $7.32M 10-Q · filed 2023-02-17 | $10.62M derived: sum of 3 quarters · filed 2023-02-17 | $13.76M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-09-30 | $2.89M 10-Q · filed 2022-11-14 | $6.20M derived: sum of 2 quarters · filed 2022-11-14 | $9.33M derived: sum of 3 quarters · filed 2022-11-14 | $11.27M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $6.44M derived: sum of 2 quarters · filed 2022-09-23 | $8.37M derived: sum of 3 quarters · filed 2022-09-23 | $9.94M 10-K · filed 2022-09-23 | ||||
| 2021-03-31 | $3.13M 10-Q · filed 2022-05-13 | $5.07M derived: sum of 2 quarters · filed 2022-05-13 | $6.63M 10-Q · filed 2022-05-13 | $8.19M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $1.93M 10-Q · filed 2022-02-14 | $3.50M 10-Q · filed 2022-02-14 | $5.06M derived: sum of 3 quarters · filed 2022-02-14 | $7.26M derived: sum of 4 quarters · filed 2022-02-14 | ||||
| 2020-09-30 | $1.56M 10-Q · filed 2021-11-10 | $3.12M derived: sum of 2 quarters · filed 2021-11-10 | $5.33M derived: sum of 3 quarters · filed 2021-11-10 | $7.84M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | $3.76M derived: sum of 2 quarters · filed 2021-09-24 | $6.27M derived: sum of 3 quarters · filed 2021-09-24 | $9.15M 10-K · filed 2021-09-24 | ||||
| 2020-03-31 | $2.20M 10-Q · filed 2021-05-13 | $4.71M derived: sum of 2 quarters · filed 2021-05-13 | $7.59M 10-Q · filed 2021-05-13 | |||||
| 2019-12-31 | $2.51M 10-Q · filed 2021-02-11 | $5.39M 10-Q · filed 2021-02-11 | ||||||
| 2019-09-30 | $2.88M 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |